Biogen has decided to close down its digital health unit, formed just two years ago, as part of a major cost-reduction drive that has already claimed thousands of jobs.
AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), in
CRISPR-based therapies are undergoing a remarkable evolution, with drug developers striving to enhance the safety, precision and efficacy of their products.
CRISPR represents the next frontier in the cell and gene therapy landscape.
Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy, robust and detailed analytics are the cornerstone of gene therapy development.
Editor's Picks
